3 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates


Anaesthesia Critical Care & Pain Medicine
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le samedi 9 mars 2019
Doi : 10.1016/j.accpm.2019.02.005
Effects of modification of trauma bleeding management: A before and after study

Cécile Guth c, Olivia Vassal a, b, Arnaud Friggeri a, b, Pierre-François Wey c, Kenji Inaba d, Evelyne Decullier e, François-Xavier Ageron f, Jean-Stéphane David a, b, c,
a Department of Anaesthesiology and Critical Care Medicine, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 69495 Pierre Benite, France 
b Université Claude Bernard Lyon 1, 69003 Lyon, France 
c Service de Santé des Armées, Hôpital d’Instruction des Armées Desgenettes, Department of Anaesthesiology and Critical Care Medicine, 69003 Lyon, France 
d Division of Trauma and Critical Care, Department of Surgery, LAC + USC Medical Center, University of Southern California, Los Angeles, California, USA 
e Pole Information Medicale Evaluation Recherche, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, 69003 Lyon, France 
f Emergency Department and SAMU 74, Annecy-Genevois Hospital, Annecy, France 

Corresponding author at: Departement d’Anesthesie-Reanimation, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, 69495 Pierre-Benite Cedex, France.Departement d’Anesthesie-Reanimation, Centre Hospitalier Lyon Sud, Hospices Civils de LyonPierre-Benite Cedex69495France

We hypothesised that the association of tranexamic acid (TXA) administration and thromboelastometry-guided haemostatic therapy (TGHT) with implementation of Damage Control Resuscitation (DCR) reduced blood products (BP) use and massive transfusion (MT).


Retrospective comparison of 2 cohorts of trauma patients admitted in a university hospital, before (Period 1) and after implementation of DCR, TXA (first 3-hours) and TGHT (Period 2). Patients were included if they received at least 1 BP (RBC, FFP or platelet) or coagulation factor concentrates (fibrinogen or prothrombin complex) during the first 24-hours following the admission.


380 patients were included. Patients in Period 2 (n  = 182) received less frequently a MT (8% vs. 33%, P  < 0.01), significantly less BP (RBC: 2 units [1–5] vs. 6 [3–11]; FFP: 0 units [0–2] vs. 4 [2–8]) but more fibrinogen concentrates (3.0 g [1.5–4.5] vs. 0.0 g [0.0–3.0], P  < 0.01). Multivariate logistic regression analysis identified Period 1 as being associated with an increased risk of receiving MT (OR: 26.1, 95% CI: 9.7–70.2) and decreased survival at 28 days (OR: 2.0, 95% CI: 1.0–3.9). After propensity matching, the same results were observed but there was no difference for survival and a significant decrease for the cost of BP (2370 ± 2126 vs. 3284 ± 3812 €, P : 0.036).


Following the implementation of a bundle of care including DCR, TGHT and administration of TXA, we observed a decrease to the use of blood products, need for MT and an improvement of survival.

The full text of this article is available in PDF format.

Keywords : Tranexamic acid, Thromboelastometry, Trauma, Coagulopathy, Blood products, Coagulation factor concentrates, Damage control

© 2019  Société française d'anesthésie et de réanimation (Sfar)@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline